Biosimilars 2019

Biosimilars 2019 will showcase the current year’s gathering is New Horizons in Biosimilars and Drug Delivery which will give a worldwide stage to talk of present and future of Biosimilars and drug delivery. Biosimilars are neither generic medicines nor novel treatments. Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (MAbs), are playing an increasingly important role in global healthcare. The phenomenally complex manufacturing process involved in making biosimilars is really leading contemporary science in this field and could potentially revolutionize the treatment of some conditions.

DETAILS OF SINGAPORE’S ANNUAL MEETING ON BIOSIMILARS AND DRUG DELIVERY:

Conference Name Place Date
Biosimilars 2019 Singapore June 24-25, 2019

Biosimilars versus generic drugs Biosimilars and generic drugs are versions of brand-name drugs. But biosimilars are not generics, and there are important differences between biosimilars and generic drugs. Both biosimilars and generics are approved through different abbreviated pathways. The manufacturer of a generic drug must demonstrate that the generic is bioequivalent to the brand name drug. Biosimilar manufacturers must demonstrate that the biosimilar is highly similar to the reference product. Biosimilars drugs should show there is no clinically meaningful differences between the biosimilar and the reference product in terms of safety and effectiveness.

Key Discussions on Biosimilars 2019

  • Current regulatory status of biosimilar medicines in the EU
  • Market access and regulatory developments
  • Sustainability of the biosimilar medicines sector
  • Advances and convergence of regulatory science
  • Regulatory requirements, scientific and operational challenges
  • Biosimilar Development and Manufacturing
  • Pharmacovigilance
  • Clinical Trials
  • Legal Considerations on Biosimilars
  • FDA-Approved biosimilar products
  • Prescribing biosimilar and generics drugs

Meet the Biosimilars Experts

Masaki Iino MD, PhD
University of Yamanashi, Japan

Prof. Gautam Sethi

National University of Singapore
Singapore

MASSIMO RADIN, MD
University of Torino, Italy

Joelle Chia
Asia Director at Pharma to Market, Singapore

Dr. Richard Littlewood
CEO and Founder of Applied Strategic, UK

Dr. Rakeshwar.B
Dr. Reddy’s Laboratories, India

Dr. BASAVARAJ K. NANJWADE
Trroy Life Sciences Pvt Ltd, India

Silvia Brandalise
Centro Infantil Boldrini, Brazil

Dr. Jasvinder Singh

University of Alabama, USA

Dr Chandraiah Godugu

NIPER,  India

Balkiss Bouhaouala
Medicine of Tunis, Biochemistry, Tunisia

Dr. Mayank Singhal
Methodist University, USA

Dr. K. Mukkanti
Emeritus Professor, JNTUH, India

Dr Gopal Natesan

Director, MAHSA University,
Malaysia

Prof.A. Jayashree
JNTUH, India

Dr.Praveen Bommu
CEO – PS3 Laboratories LLP, India

Call for Abstracts

The Biosimilars Summit invites abstracts related to the new scientific research in all the fields of Biosimilars and Drug Delivery & its related aspects. Registrants are invited to submit an abstract for consideration for oral and poster presentation. In general, we encourage more specific to the current research fields representing innovation and recent technologies. Abstracts received will be reviewed by a scientific committee from aspirants and categorized as speaker talks and poster presentations.

  • Clinical Trials
  • Pharmacovigilance
  • Prescribing biosimilar and generics drugs
  • FDA-Approved biosimilar products
  • Regulatory requirements, scientific and operational challenges
  • Sustainability of the biosimilar medicines sector

Our Partners